Objective: To evaluate the effects of pharmacological preconditioning with a volatile anesthetic in patients undergoing liver resection with inflow occlusion. Background: In liver surgery, ischemic preconditioning and intermittent clamping are the only established protective strategies to reduce tissue damage due to ischemia during inflow occlusion. Preconditioning with volatile anesthetics has provided protection against cardiac and renal ischemic injury in several animal models through NO and HO-1 pathways. But pharmacological preconditioning has never been tested in patients undergoing liver surgery in a randomized trial. Methods: Sixty-four patients undergoing liver surgery with inflow occlusion were randomized intraoperatively for preconditioning with sevoflurane or not (ClinicalTrials.gov NCT00516711). Anesthesia was performed intravenously with propofol. Thirty minutes before inflow occlusion propofol was replaced by sevoflurane in the preconditioning group. Primary endpoint was postoperative liver injury assessed by peak values of liver transaminases. Postoperative complications were recorded according to an established scoring system. Results: Sevoflurane preconditioning significantly limited the postoperative increase of serum transaminase levels by 261 U/L (95% CI, 65 to 458; P ϭ 0.01) for the ALT and by 239 (95% CI, Ϫ2 to 480; P ϭ 0.05) for the AST corresponding to decreases of baseline levels of 35% and 31%, respectively. Patients with steatosis had an even better benefit than patients without steatosis. The rates of any complication (risk ratio 0.46; 95% CI, 0.25 to 0.85; P ϭ 0.006) and of severe complications requiring invasive procedures (risk ratio 0.25; 95% CI, 0.06 to 1.08; P ϭ 0.05) were also lowered by preconditioning. Conclusion: This first randomized trial of pharmacological preconditioning in liver surgery in humans showed a protective effect of preconditioning with volatile anesthetics. This strategy may provide a new and easily applicable therapeutic option to protect the liver and to lower complication rates. (Ann Surg 2008;248: 909 -918) From the *Swiss HPB (Hepato-Pancreatico-Biliary) Center, †Institute of Anesthesiology, ‡Department of Surgery, §Department of Physiology,
H emorrhage remains a significant concern during major liver resection influencing postoperative recovery and long-term survival. 1, 2 Inflow occlusion by clamping of the portal triad (Pringle maneuver), as routinely used in many centers, 3 prevents blood loss during liver transsection, 4 -6 particularly when associated with low central venous pressure (CVP). 7 However Pringle maneuver induces ischemic injury in the remnant liver, which is associated with increased morbidity and mortality. 8 Diseased livers such as steatotic or fibrotic livers may be the most vulnerable to temporary interruption of blood flow. 9 -11 Surgical techniques are known to protect liver cells against subsequent sustained ischemia in cases of ischemicreperfusion injury in animal models 12 and in humans. 11, 13 Currently, ischemic preconditioning with continuous clamping and intermittent portal triad clamping (cycles of 15 minutes of ischemia followed by 5 minutes of reperfusion) are the only clinically established protective strategies against liver injury due to prolonged ischemia. 14, 15 The underlying protective principle of ischemic preconditioning and intermittent clamping is a limitation of stress exposure of the liver that triggers natural defense mechanisms against subsequent ischemic insults. 16 Pharmacological preconditioning as a hepatoprotective strategy in humans has not yet been described, whereas volatile anesthetic agents such as isoflurane or sevoflurane have been widely studied to attenuate cardiac mechanical dysfunction and limit ultrastructural abnormality on reperfusion after ischemia in the myocyte. 17, 18 Intravenous anesthetics such as propofol do not seem to have comparable protective properties. 19 It has been shown in a rat model that the application of isoflurane before induction of hepatic ischemia protected the liver from ischemia-reperfusion injury. 20 Therefore, we designed a randomized controlled trial (RCT) to evaluate the protective effects of sevoflurane preconditioning in patients undergoing hepatectomy under inflow occlusion. In the presence of sevoflurane, an attenuation of liver injury is hypothesized on the basis of a diminished increase of liver transaminases. Our secondary endpoint was to evaluate the impact of sevoflurane preconditioning in reducing postoperative complications. Finally, we evaluated inducible nitric oxide synthase (iNOS) expression in liver tissue. Nitric oxide (NO) has been proposed to mediate the beneficial effects of ischemic preconditioning in the liver. 21, 22 It also seems to play an essential role in pharmacological preconditioning with isoflurane in myocytes. 23 
MATERIALS AND METHODS

Experimental Design
Consecutive patients undergoing elective liver resection with inflow occlusion between April 2006 and November 2007 were assessed for study eligibility. Exclusion criteria for the present study were age Ͻ18 years, liver cirrhosis, additional ablation therapies (cryosurgery or radiofrequency), living donors, and liver resections without inflow occlusion. Enrolled patients were randomized at the beginning of the operation into an intervention group (preconditioning with sevoflurane/ sevoflurane group) or a control group (propofol group). The randomization sequence without any stratification was generated by computer and sealed, consecutively numbered envelopes provided concealment of random allocation. Each patient was operated under the supervision of 1 of 2 blinded, experienced hepatobiliary surgeons. The time of continuous inflow occlusion was adapted as needed but had to exceed 30 minutes.
The study was approved by the institutional review board for human studies and internationally registered at ClinicalTrials.gov NCT00516711. The manuscript complies with the CONSORT checklist. Written informed patient consent was obtained from all participants.
Anesthesia
All patients received oral midazolam (7.5 mg) as a premedication. Electrocardiogram, radial arterial pressure, arterial oxygen saturation (SaO 2 ), and depth of anesthesia (measured by bispectral index) were monitored routinely. If necessary, thoracic epidural anesthesia was performed using continuous application of 0.33% ropivacaine (4 -8 mL/h with a bolus application of 4 mL after induction of anesthesia). General anesthesia was induced with 3 g/kg fentanyl, tar-get-controlled infusion of propofol, set at a plasma target concentration of 4 to 6 g/mL, and 0.5 mg/kg atracurium. Anesthesia was maintained with target-controlled infusion of propofol (plasma target concentration of 2-4 g/mL), fentanyl 1 to 2 g/kg, and atracurium 5 to 10 mg boluses according to clinical needs and remifentanil 0.3 to 0.6 g/ kg/min. Both the control and preconditioning group had the same protocol for application of fentanyl and remifentanil.
In patients with preconditioning propofol anesthesia was replaced by sevoflurane according to a previous protocol from cardiac preconditioning in ischemia-reperfusion ( Fig.  1 ). 24, 25 Thirty minutes before induction of ischemia, propofol anesthesia was stopped and replaced by sevoflurane (induction of 5 minutes). Pharmacological preconditioning with endexpiratory sevoflurane of 3.2 vol % (according to a minimal alveolar concentration of 1.5) was performed for 10 minutes. The following 15 minutes were used to stop sevoflurane application and to replace it by propofol (washout of 15 minutes). Ischemia was then started for at least 30 minutes. The hemodynamic tolerance to clamping was the same in both groups.
Surgical Procedure
Surgical procedures were performed in a standardized manner under the supervision of 2 experienced HPB surgeons. A first liver specimen was taken after laparotomy (baseline biopsy). During mobilization of the liver, the time point of 30 minutes before clamping of the portal triad was defined by the surgeon and communicated to the anesthesiologist. According to the randomization, a pharmacological preconditioning with sevoflurane was performed or not, whereby the surgeon was kept blinded for the whole operation. Selective devascularization of the resected specimen was carried out in anatomic resections 11 but not in atypical hepatectomies. During resections, a low CVP (0 -5 mm Hg) was required. Liver transsection was performed by parenchyma crushing using a small Kelly clamp (3-mm diameter tip). 6 Small vessels (Ͻ2 mm) were coagulated with the irrigated bipolar forceps set at 120 W, whereas all other structures including major intrahepatic bile ducts were ligated or clipped. A stapler device was only used for the transsection of the hepatic veins. The time of continuous inflow occlusion was adapted as needed but had to exceed 30 minutes, as this is the minimal ischemic period with detectable postoperative liver injury. 5 Inflow occlusion was achieved by the tourniquet technique around the portal triad with a 4-mm mersilene tape. Separate clamping of aberrant left hepatic arteries was carefully performed when present. Thirty minutes after reperfusion, a second biopsy was performed.
Endpoints
Each patient was followed for the entire hospitalization. The primary endpoint was postoperative hepatocyte injury defined by peak alanine-aminotransferase (ALT) and aspartate-aminotransferase (AST) levels over 7-postoperative days. The secondary endpoint was postoperative complications as assessed by our treatment-oriented complication score. 26 Grades I, II, and IIIa were assessed as minor, whereas grades IIIb, IV, and V were major complications, requiring interventions with general anesthesia and/or intensive care management (for more details, please consult www.surgicalcomplication.info). Additional endpoints were peak values of white blood cells (WBC), bilirubin, alkaline phosphatase (ALP), creatinine levels, length of hospital stay, length of intensive care unit (ICU) stay, and operating time. Additionally, histologic evaluation of steatosis and fibrosis and the quantification of iNOS gene expression were determined.
Histologic Evaluation
Liver resection specimens or intraoperative liver biopsies (baseline biopsy) were evaluated by a single pathologist (W.J.) for the presence of steatosis and fibrosis. Using hematoxylin and eosin (H&E) stained sections, the degree of total steatosis was graded as absent (Ͻ10%), mild (10%-30%), moderate (Ͼ30%-60%), or severe (Ͼ60%) based on the percentage of hepatocytes with fat droplets. Liver fibrosis was quantified according to the METAVIR score using Sirius red-stained sections: absent (F0), portal fibrosis without septa (F1), portal fibrosis with rare septa (F2), numerous septa (F3), and cirrhosis (F4). 27 Histologic analysis was performed without knowledge of the postoperative outcome of patients.
Determination of Inducible Nitric Oxide Synthase
Total RNA was extracted from both biopsies and reverse transcribed using a special kit (Taqman Reverse Transcription Reagents). Quantitative PCR (QPCR) was carried out with a 7500 Fast Real Time PCR System. The following primers were used for the QPCR: human iNOS (Hs00167257-m1) and human 18S (Hs99999901-s1). QPCR was performed using Taqman Universal PCR Mastermix (Nr. 4304437) according to the manufacturer's protocol. Gene expression was normalized to 18S, and increase in iNOS gene expression was calculated with the comparative C T method of gene expression before and after ischemia, respectively. iNOS gene expression from baseline biopsy was assigned as value of 1. All products were purchased from Applied Biosystems, Foster City, California.
Statistical Analysis
In an intention-to-treat analysis, we first compared peak transaminases (primary outcome) between groups using a linear regression model with peak transaminases as the dependent and group allocation as the independent variable (corresponding to a 2-sample t test) and expressed differences between groups as mean differences with 95% confidence intervals. In addition, we adjusted these comparisons for baseline transaminases and bilirubin levels for preoperative chemotherapy (yes/no) and Pringle time in multivariable linear regression analyses (ANCOVA). We checked the distribution of residuals, which were distributed normally. We repeated these analyses for the secondary continuous outcomes. We calculated risk ratios for binary outcomes (complications) and tested for statistical significance using Fisher exact test. Again, we adjusted the comparisons of binary data for baseline transaminases and bilirubin levels for preoperative chemotherapy (yes/no) and Pringle time by using multivariable logistic regression analyses.
We conducted a limited number of subgroup analyses with 3 prespecified predictors that may modify the effects of pharmacological preconditioning on postoperative hepatocyte injury (ALT/AST). We assessed the effect of steatosis (yes/ no, defined by the presence of at least 10% of hepatocytes containing fat droplets), preoperative chemotherapy (yes/no), and age (Ͻ60years/Ն60 years) by introducing interaction terms into the regression analyses, which is the most rigorous and widely recommended approach for subgroup analyses. 28 Because of the low power of interaction testing to detect subgroup effects, we considered subgroup effects to be significant if P Յ 0.10. 29 All analyses were conducted using STATA (STATA for Windows, version 9.2, Stata Corp; College Station, TX). Figure 2 shows the study flow from screening of potential participants to the final assessment. The main reason for noninclusion of a number of patients was the concomitant availability of a second randomized controlled trial focusing on liver regeneration after major liver resection. Furthermore, after randomization, 6 patients had to be excluded because of violation of the study protocol due to the intraoperative decision of an approach without Pringle maneuver (2 patients in the control group) or because of a delay of more than 30 minutes between preconditioning and hepatic inflow occlusion (4 patients in the preconditioning group).
RESULTS
What Was the Patient Selection for Study Participation?
Was the Preconditioning Group Comparable With the Control Group?
Thirty patients were included in the preconditioning group (sevoflurane group) and 34 patients in the control group (propofol group). Table 1 shows the patients characteristics and baseline values of the outcome parameters. The mean age was slightly different, 54.2 years in the sevoflurane group versus 57.8 years in the control group, with 16 and 19 males, respectively. American Society of Anesthesiologists (ASA) physical status classification, type of disease, histology of liver parenchyma, and the use of chemotherapy prior Annals of Surgery • Volume 248, Number 6, December 2008 Pharmacological Preconditioning in Liver Surgery resection were distributed similarly between both groups. None of the parameters were statistically different. Thirty-three patients were operated for liver metastasis from colorectal cancer, 6 for echinococcosis, 3 for hepatocellular carcinoma, 3 for cholangiocarcinoma, 1 for a neuroendocrine tumor, 11 for other benign lesions such as liver adenoma, focal nodular hyperplasia, hemangioma or cysts, and 7 for other malign tumors (various kinds of metastatic diseases) ( Table 1) . Twenty-eight patients underwent a major hepatectomy, of whom 8 had an anatomic right hemi-hepatectomy (SV to VIII), 5 had a left hemi-hepatectomy (SI to IV), 7 had extended right hemi-hepatectomy (SIV to VIII), and 8 had an atypical major resection ( Table 2 ). Associated procedures were adrenalectomy, abdominal hernia repair, vascular repair, and lymphadenectomy in the hepatoduodenal ligament. Intraoperative parameters as shown in Table 2 were similar in both groups. The mean time of inflow occlusion was 36 minutes (sevoflurane group) and 35 minutes (control group) respectively, whereas the operating time was around 4 hours. 
Did Pharmacological Preconditioning Prevent Postoperative Liver Injury?
The degree of ischemia and reperfusion injury of the liver was assessed by postoperative peak serum ALT and AST levels. The peak of the transaminases occurred between 6 hours after the end of surgery and the third postoperative day. In most of the patients, ALT and AST levels returned to normal within 7 days. Sevoflurane preconditioning significantly lowered peak ALT levels by 261 U/L (95% CI, 65 to 458; P ϭ 0.01) and AST levels by 239 U/L (95% CI, Ϫ2 to 480; P ϭ 0.05) corresponding to decreases of baseline levels of 35% and 31%, respectively ( Table 3 ). Unadjusted and adjusted results were almost identical. Other liver parameters such as bilirubin and ALP, but also peak values of white blood cells and creatinine did not reach statistical differences.
Did Pharmacological Preconditioning Influence the Clinical Outcome After Liver Surgery?
One patient in each group (both underwent extended right hemihepatectomy for hilar cholangiocarcinoma) died within 1 week after major hepatectomy. Death occurred due to sepsis. The complication rate was significantly lower in the sevoflurane group compared with the propofol group (30% vs. 65%; risk ratio 0.46; 95% CI 0.25 to 0.85; P ϭ 0.006) ( Table 4 ). There were no significant differences regarding minor complications among grade I, II, and IIIa. However, major complications (grade IIIb, IV, and V) differed significantly between groups with 6.7% versus 26.5% (P ϭ 0.05). Major complications were sepsis (4 patients), bilioma (2 patients), bleeding (2 patients), and localized intraabdominal infection (3 patients). The mean hospital stay was 2 days shorter in the sevoflurane group (11 vs. 13 days) but without statistical significance. Intensive care unit stay was comparable between groups.
Is Inducible Nitric Oxide Synthase Involved in Cellular Signaling in Pharmacological Preconditioning in Liver?
Expression of iNOS mRNA was compared between preand postresection liver biopsies. iNOS mRNA was significantly up-regulated in the preconditioning group (5.96 Ϯ 7.12) compared with the control group (1.3 Ϯ 1.15; P ϭ 0.001) in (Table 3) .
Does Liver Steatosis, Preoperative Chemotherapy, or Age of Patients Influence the Protective Effect of Pharmacological Preconditioning?
Thirty of 64 patients (47%) had steatosis with Ͼ10% of hepatocytes-containing fat droplets (9 of these patients had more than 30%). As shown in Figures 3A, B , pharmacological preconditioning demonstrated strong protective effects in steatotic patients in terms of postoperative serum peak ALT und AST levels compared with nonsteatotic patients. Subgroup effects were significant for both peak ALT (P ϭ 0.03) und AST levels (P ϭ 0.08). Although preoperative chemotherapy favored preconditioning with differences in peak transaminases between control and preconditioning group in patients with chemotherapy of 361 U/L (ALT) and 430 U/L (AST) compared with 174 U/L and 16 U/L without chemotherapy, results were not significantly different (Figs. 3A, B) . Also no significant difference was found for the effect regarding age. The difference in peak ALT between control and preconditioning group was 481 U/L (554 U/L for AST) in 
DISCUSSION
This randomized controlled trial demonstrates for the first time the protective effects of pharmacological preconditioning in patients undergoing liver resection with inflow occlusion. Not only was postoperative liver injury attenuated, as measured by serial serum levels of transaminases, but also clinical outcome was significantly improved by pharmacological preconditioning. The observed protective effects were more pronounced in patients with liver steatosis. This study additionally suggests that NO may mediate the protective pathway of volatile anesthetics.
Numerous strategies have been designed to reduce ischemia-reperfusion injury after liver resection. Basically, inflow occlusion is less harmful than total vascular exclusion. 30 Two protective strategies to prevent ischemic-reperfusion injury have been clinically accepted: ischemic preconditioning 5, 11, 31 and intermittent clamping 14, 32 of the portal triad. Ischemic preconditioning consists of a short period of inflow occlusion, usually 5 to 10 minutes, followed by 5 minutes of reperfusion before the actual inflow occlusion for the operation. Intermittent clamping consists of 10 minute intervals of reperfusion during the whole period of the operation, and although apparently more protective, may lead to significant blood loss. 14 Both procedures require a surgical intervention and prolong the overall time of the surgical procedure. Hence, a pharmacological approach not requiring additional surgical procedures is a more attractive alternative than the established surgical strategies.
Pharmacological preconditioning with a volatile anesthetic is a new approach in liver surgery. Beneficial results in clinical trials, particularly of preconditioning with sevoflurane, have been shown in cardiac surgery, 33, 34 whereas in liver surgery, only 1 animal study is available. 20 This study established for the first time that volatile anesthetics confer protection to livers exposed to ischemia and reperfusion in patients requiring major liver surgery.
The study design, particularly regarding the endpoints, was based on our previous clinical 5, 11, 14 and experimental [35] [36] [37] experience with such studies. Patients with cirrhosis were excluded from the study because there might have been different and more severe effects of inflow occlusion. Additionally, some patients were not included because they were already participating in another ongoing randomized controlled trial (RCT), focused on regeneration after major liver resection. At our center, more than 95% of the patients with liver resections are included in prospective studies. This high inclusion rate is not normally attainable by 1 single RCT due to predefined inclusion and exclusion criteria. At our center, we aim to have at least 2 parallel ongoing trials to make participation in a RCT possible for almost all of our patients. On the other hand, some interferences concerning inclusion of patients between patients can occur. As shown in Figure 2 , patient collection was consecutive and unselective aside of the parallel RCT.
Considering the entire series, we found statistically significant protection from preconditioning with sevoflurane in terms of postoperative peak ALT and AST levels. These results highlight the overall protective effects against reperfusion injury considering the heterogeneous groups of patients with ischemic times of 30 to 50 minutes, the often use of additional procedures, and patients with or without hepatic steatosis. The results were adjusted according to potential confounders (Table 3) to exclude any influence of minimal differences between the patient groups, which occur despite the randomization of patients. The decrease of peak transaminases due to pharmacological preconditioning of around 30% seems comparable to the effect of ischemic preconditioning. 11 Postoperative morbidity and mortality were evaluated using a standardized classification system enabling stratification of complications by severity. 26 The overall morbidity rate of 45%, the mortality rate of 3%, and the incidence of severe complications (grades IIIb to V) of 17% were comparable to previously published data after liver resection. 11, 14, 38, 39 The present study demonstrated significantly improved clinical outcome after pharmacological preconditioning: on the one hand regarding overall complication rates (65% vs. 30%; P ϭ 0.006) and on the other regarding major complication (grade IIIb to V) (27% vs. 7%; P ϭ 0.05). This finding underscores the potentially powerful protective effects of volatile anesthetics, as none of the previous trials on surgical preconditioning or intermittent clamping could show significant differences regarding clinical outcome. A possible explanation for this phenomenon might be the release of inflammatory mediators upon hepatic ischemia-reperfusion, which could also trigger a proinflammatory cascade in organs other than the liver. Several studies have stressed the impor-tance of toll-like receptor4 (TLR4) in the pathophysiology of ischemia-reperfusion in the heart, 40 kidney, 41 and liver. 42 Theoretically, mediators released upon reperfusion might also induce TLR4 expression in other organs, where the systemic application of the volatile anesthetic could interfere, either by decreasing enhanced TLR4 expression or by blocking these receptors. Further studies have to be performed to gain more insight into these signaling pathways.
The mechanisms of protection of hepatocytes due to pharmacological preconditioning remain unclear and may involve several pathways. Barrier et al 22 demonstrated the modulation of gene expression due to ischemic preconditioning. Particularly the up-regulation of iNOS might underline the hypothesis that preconditioning has been linked to NO production. In our study, the expression of iNOS upon reperfusion significantly increased compared with the baseline value in the preconditioning group, although the second liver biopsy was performed after only 30 minutes of reperfusion. This points to a possible protective role of NO in pharmacological preconditioning. NO is also a key signaling component involved in preconditioning elicited by volatile anesthetics in the myocyte, activating protein kinase C, 23 which ultimately activates sarcolemmal and mitochondrial K ATP channels.
There is growing evidence that liver steatosis is associated with impaired outcome after hepatic resection. 43, 4445 Subgroup analysis of previous studies has demonstrated a higher protective effect of ischemic preconditioning 5 and intermittent clamping 14, 32 in steatotic livers, an effect possibly associated with the preservation of ATP during ischemia. 11 Our data confirm higher degree of protection in steatotic livers, also by pharmacological preconditioning (Figs. 3A, B ). Although this study was small for subgroup analyses and despite the fact that interaction testing has low power to detect subgroup effects, we found strong effect modification by steatosis (P for subgroup analysis ϭ 0.03 for ALT and 0.08 for AST). We considered the subgroup effects to be significant if P values for the interaction term was Ͼ0.10 because of the low power of this test as did others. 29 Previous studies have demonstrated this effect in liver steatosis of Ͼ25% and Ͼ30%, respectively. 11, 14 An increasing number of patients with tumors undergo extensive chemotherapy with multiple drugs before surgery, impairing the postoperative outcome. 8 Drugs such as irinotecan (Campto, Pfizer) and, to a lesser degree, oxaliplatin (Eloxatin, Sanofi, Aventis) have been associated with the development of steatohepatitis, 46, 47 whereas bevacizumab (Avastin, Hoffmann-LaRoche), a monoclonal antibody, impairs liver regeneration and wound healing through its regulation of angiogenesis. 48, 49 The present study did not show a significant improvement of the protective effect in chemotherapeutic livers (Figs. 3A, B) . The sample size to negate this effect definitively might have been too small and needs to be addressed in larger studies.
In contrast to previous observations in ischemic preconditioning, age had no significant influence on the protective effect of pharmacological preconditioning (Figs. 3A, B) . However, the beneficial effect was higher in patients above 60 years. We previously identified age as a factor influencing the effect of ischemic preconditioning in a multivariate analysis and suggested that tolerance of hepatocytes against ischemic injury might be different in younger compared with older patients. 11 The age limit for ischemic preconditioning was approximately 60 years, and only patients with age below benefited from this strategy.
Although the results of the primary endpoint showed a number of significant effects, the sample size is relatively small. Therefore interpretation of subgroup analysis, in particular, needs to be done carefully. This trial is focused on blood parameters and clinical outcome, while a pathway of the protective effect can be hypothesized. Investigations concerning the mechanism in animal models are requested. Further trials on the protective effect of different applications of sevoflurane would be of major interest.
Although sevoflurane has been successfully tested in several conditioning setups in cardiac surgery, 34 we were primarily interested to compare our new established preconditioning protocol with previously evaluated surgical "preconditioning" techniques, which are known to protect liver cells against subsequent sustained ischemia.
In conclusion, this trial provides evidence of the protective effect of preconditioning with volatile anesthetics on ischemic/reperfusion injury in patients with liver resection. Pharmacological preconditioning prevents hepatic injury defined by low levels of transaminases but also improves the clinical outcome, particularly in patients with an increased risk of postoperative liver failure such as those with steatosis. This strategy, although needing further investigations, may provide a new and easily applicable therapeutic option to protect the liver.
Secondly, in your article, you excluded patients with liver cirrhosis. You could demonstrate that patients with steatosis benefited more than patients without steatosis. In our clinical practice, many patients received chemotherapy and experience other damages before liver resection. Do you think the same results would be found in patients with altered liver parenchyma, for instance, those with preoperative neoadjuvant chemotherapy for colorectal cancer?
B. BECK-SCHIMMER: Your comment regarding volatile anesthetics is absolutely correct. Although sevoflurane has a metabolic rate of 4%, desflurane does not undergo metabolism. Data from cardiac surgery show that desflurane also has a protective effect in ischemia-reperfusion injury. We are not sure but we assume that all kinds of volatile anesthetics might induce protection. In our study, we used sevoflurane, as we have more experience with this volatile anesthetic regarding protection in injury models. For example, our group evaluated the possible effect of sevoflurane in an in vitro and in vivo model of acute lung injury, where we demonstrated an attenuation of inflammation with the application of sevoflurane.
To your second question: we also looked at a subgroup effect regarding chemotherapy, and we did not find statistically significant differences between preconditioning and control groups. However, the trend we observed showed that patients with chemotherapy might benefit more from preconditioning. P. CLAVIEN: Dr Neuhaus, your question regarding protection in a damaged liver, such as that due to chemotherapy, is important, and we may only speculate on the beneficial effects of sevoflurane in this population. Chemotherapy, as induced by irinotecan or oxaliplatin for example, typically induces steatotic changes in hepatocytes in addition to inflammatory changes mimicking steatohepatitis. One of the possible key mechanisms of this new preconditioning approach is a potent anti-inflammatory effect, and therefore, it may confer increased protection in this population.
H. BISMUTH: I have the feeling that you used continuous inflow occlusion. Why? It has been shown that intermittent inflow occlusion produces better hepatic tolerance than continuous occlusion.
B. BECK-SCHIMMER: We attempted to compare 2 different preconditioning procedures in our study design: surgical and pharmacological preconditioning, and I would like to let Professor Clavien address this issue. P. CLAVIEN: We reported a randomized controlled trial comparing intermittent versus ischemic preconditioning plus continuous clamping for major liver resection 2 years ago in the Annals of Surgery (244(6):921-930, December 2006). We found no difference between the 2 groups for up to a total clamping time of 1 hour. An advantage of the continuous clamping was the avoidance of bleeding, which occurred during each reperfusion period in the intermittent clamping group. Therefore, we selected a study design with continuous clamping, ranging between a minimum of 30 minutes and not exceeding 1 hour. Most extensive liver resections can be performed during this clamping time. This design also enabled us to directly assess the effects of preconditioning with sevoflurane versus ischemic preconditioning. We have just initiated another randomized trial, comparing intermittent clamping with new conditioning protocols including volatile anesthetic, as you are correct that intermittent clamping is superior to ischemic preconditioning for ischemic time extending beyond an hour. D. JAECK: I have 2 questions. In your definition of major resection, you said that it is with 4 segments or more, which is not usual, it is usually 3 segments, so why did you choose 4 segments? Was it for statistical reasons? Second question, you just showed that the highest benefit was for the patient with steatosis but you did not mention which steatosis (macro or micro)? Which level of steatosis?
B. BECK-SCHIMMER: To answer your second question, patients with more than 10% steatosis were included in the "steatosis group." To your first question, we have to change the definition to less than 3 segments for minor resection and 3 segments and more for major resection. This does not have any implications regarding statistical analysis. R. PLOEG: Several years ago, Pierre Clavien gave us a beautiful report on how to reduce tissue injury during hepatectomy with ischemic clamping. Despite the fact that his group observed an improved outcome, there was something very striking: the beneficial effect was age dependant. In fact, in patients older than 65 years, it even became detrimental to clamp and invoke ischemic preconditioning. In this respect, I wondered whether you checked in your positive series for this age dependency and detrimental factor. And, if so, were you able to overcome this negative effect with your volatile approach? B. BECK-SCHIMMER: You raise a good point. We did not see a positive effect regarding the age of the patients, but the total number of patients enrolled in the study was not high. Again, we observed a trend showing that sevoflurane preconditioning might favor a group of patients older than 60 years. Comparing ischemic and pharmacological preconditioning, we do not know if these 2 procedures follow the same cellular signaling pathways, inducing the same protection.
J. FIGUERAS: You demonstrated that the transaminases were higher in the group without preconditioning but you did not find differences in liver insufficiency, and I suppose that the bleeding was similar. I am surprised that you experienced more complications in the group without preconditioning. Complications after liver surgery are mainly related to 2 B. BECK-SCHIMMER: Complications were observed in both groups but with a smaller incidence in patients with preconditioning. Complications included liver failure, kidney failure, and acid aspiration among other things. P. CLAVIEN: Thank you, Dr. Figueras, for this important observation. We were also surprised by the significant benefits of sevoflurane preconditioning in preventing postopera-tive complications. In the discussion of the manuscript, we speculate that sevoflurane may confer potent systemic antiinflammatory effects, whereas the protective effects of the surgical strategies, ischemic preconditioning, or intermittent clamping may be limited to the liver. Thus, it may well be that this pharmacological approach may provide new powerful protection not only on the liver but on all other organs subjected to injury during major hepatic surgery. This may also underscore that we still do not understand much about the underlying mechanisms of many complications after major hepatic surgery.
